Seramun has successfully developed an ELISA and a macroarray to improve SARS-CoV-2 antibody diagnostics. The RBD assay has so far been tested with 64 sera of COVID-19 patients and 218 negative blood donor sera. Sensitivity = 90.6% and specificity = 100% were determined. The SeraSpot macroarray contains a total of 4 different antigens, which greatly increases the security of SARS-CoV-2 serological diagnostics. Thus, a highly specific detection of SARS-CoV-2 antibodies is possible.